❗[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

A New Revolutionary Nerve-Sensing Technology That Every Investor Should Research ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe A Message from Autonomix Autonomix is aiming to shrink today's diagnostic lab equipment down to the size of a two-millimeter microchip placed on a catheter that can detect and target nerve signals. And you can invest before their planned Nasdaq listing. This potentially groundbreaking technology is intended to be the equivalent of a GPS for the nervous system, which could unlock new treatments for everything from high blood pressure to pain. Imagine treating pain by altering the nerves instead of relying on prescriptions like opioids. Autonomix's tech has over 100 patents, a strong edge against potential copycats as they tackle this estimated $100B market opportunity. While they plan to list on the Nasdaq, our readers don't have to wait until then to invest. Become an Autonomix shareholder today.

Thank you for subscribing to The Early Bird, MarketBeat's 7:00 AM newsletter that covers stories that will impact the stock market each day.   This message is a paid advertisement sent on behalf of Autonomix, a third-party advertiser of The Early Bird and MarketBeat.     This message is a paid advertisement for Autonomix from Autonomix and Strikepoint. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $15,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Autonomix or Strikepoint. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Autonomix on their website for additional information about Autonomix and their Regulation A offering.     If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you no longer wish to receive email from The Early Bird, you can unsubscribe.   © 2006-2023 American Consumer News, LLC dba MarketBeat. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.   Today's Bonus Content: The A.I. Trend Has These 7 Stocks Set To Soar